Boston Scientific Co. (NYSE:BSX) Shares Sold by Robeco Schweiz AG

Robeco Schweiz AG trimmed its position in Boston Scientific Co. (NYSE:BSX) by 27.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 268,508 shares of the medical equipment provider’s stock after selling 102,568 shares during the period. Robeco Schweiz AG’s holdings in Boston Scientific were worth $15,522,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BSX. Bruce G. Allen Investments LLC acquired a new stake in Boston Scientific in the 4th quarter worth about $28,000. Sachetta LLC purchased a new position in Boston Scientific in the 4th quarter worth approximately $32,000. Frazier Financial Advisors LLC purchased a new position in Boston Scientific in the 4th quarter worth approximately $32,000. Jones Financial Companies Lllp lifted its stake in Boston Scientific by 53.0% in the 4th quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 193 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its stake in Boston Scientific by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 215 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Boston Scientific stock traded down $0.22 during mid-day trading on Tuesday, reaching $77.20. The company had a trading volume of 141,184 shares, compared to its average volume of 6,324,944. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $77.56. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. The company has a market capitalization of $113.26 billion, a P/E ratio of 65.07, a P/E/G ratio of 2.65 and a beta of 0.81. The stock’s 50-day simple moving average is $72.36 and its 200-day simple moving average is $65.55.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The business had revenue of $3.86 billion during the quarter, compared to analysts’ expectations of $3.68 billion. On average, equities analysts predict that Boston Scientific Co. will post 2.32 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on BSX shares. Argus lifted their price target on shares of Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. Mizuho lifted their price target on shares of Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, May 15th. Royal Bank of Canada lifted their price target on shares of Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research report on Thursday, April 25th. Robert W. Baird lifted their price target on shares of Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a research report on Thursday, April 25th. Finally, Raymond James lifted their price target on shares of Boston Scientific from $73.00 to $85.00 and gave the company a “strong-buy” rating in a research report on Thursday, April 25th. Two equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $76.70.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 9,818 shares of Boston Scientific stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the sale, the director now directly owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Boston Scientific news, Director Edward J. Ludwig sold 9,818 shares of Boston Scientific stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the sale, the director now directly owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 17,587 shares of Boston Scientific stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,620,617. The disclosure for this sale can be found here. Insiders sold a total of 81,627 shares of company stock valued at $5,937,353 in the last ninety days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.